Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …

This review will focus on the process of amyloid-type protein aggregation. Amyloid fibrils are
an important hallmark of protein misfolding diseases and therefore have been investigated …

Alzheimer's disease (AD) challenges our society with an annual estimated cost of $1.08
trillion in the United States alone by 2050. 1 AD is a progressive irreversible neurological …

Soluble amyloid-β oligomers (Aβo) trigger Alzheimer's disease (AD) pathophysiology and
bind with high affinity to cellular prion protein (PrP C). At the postsynaptic density (PSD) …

Amyloid-beta (Aβ) oligomers are thought to trigger Alzheimer's disease pathophysiology.
Cellular prion protein (PrPC) selectively binds oligomeric Aβ and can mediate Alzheimer's …

Objective Currently no effective disease‐modifying agents exist for the treatment of
Alzheimer disease (AD). The Fyn tyrosine kinase is implicated in AD pathology triggered by …

Most neurodegenerative diseases such as Alzheimer's disease, type 2 diabetes, Parkinson's
disease, etc. are caused by inclusions and plaques containing misfolded protein …

Amid controversy, the cellular form of the prion protein PrPc has been proposed to mediate
oligomeric amyloid-β (Aβ)-induced deficits. In contrast, there is consistent evidence that the …

Alzheimer's disease (AD) is a devastating neurodegenerative disorder, afflicting more than
one-third of people over the age of 85. While many therapies for AD are in late-stage clinical …

Alzheimer′ s disease (AD) is the most common form of dementia in the elderly. Memory
loss in AD is increasingly attributed to soluble oligomers of the amyloid‐β peptide (AβOs) …